The paraoxonase (PON) gene cluster contains three adjacent gene members, PON1, PON2, and PON3. Originating from the same fungus lactonase precursor, all of the three PON genes share high sequence identity and a similar β propeller protein structure. PON1 and PON3 are primarily expressed in the liver and secreted into the serum upon expression, whereas PON2 is ubiquitously expressed and remains inside the cell. Each PON member has high catalytic activity toward corresponding artificial organophosphate, and all exhibit activities to lactones. Therefore, all three members of the family are regarded as lactonases. Under physiological conditions, they act to degrade metabolites of polyunsaturated fatty acids and homocysteine (Hcy) thiolactone, among other compounds. By detoxifying both oxidized low-density lipoprotein and Hcy thiolactone, PONs protect against atherosclerosis and coronary artery diseases, as has been illustrated by many types of in vitro and in vivo experimental evidence. Clinical observations focusing on gene polymorphisms also indicate that PON1, PON2, and PON3 are protective against coronary artery disease. Many other conditions, such as diabetes, metabolic syndrome, and aging, have been shown to relate to PONs. The abundance and/or activity of PONs can be regulated by lipoproteins and their metabolites, biological macromolecules, pharmacological treatments, dietary factors, and lifestyle. In conclusion, both previous results and ongoing studies provide evidence, making the PON cluster a prospective target for the treatment of atherosclerosis. Antioxid. Redox Signal. 16, 597–632.
AckermanZ, Oron-HermanM, PappoO, PelegE, SafadiR, Schmilovitz-WeissH, GrozovskiM. Hepatic effects of rosiglitazone in rats with the metabolic syndrome. Basic Clin Pharmacol Toxicol, 107:663–668. 2010.
3.
AdkinsS, GanKN, ModyM, La DuBN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet, 52:598–608. 1993.
4.
AharoniA, GaidukovL, YagurS, TokerL, SilmanI, TawfikDS. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci U S A, 101:482–487. 2004.
5.
AhmadS, CarterJJ, ScottJE. A homogeneous cell-based assay for measurement of endogenous paraoxonase 1 activity. Anal Biochem, 400:1–9. 2010.
6.
AhmedZ, BabaeiS, MaguireGF, DraganovD, KuksisA, La DuBN, ConnellyPW. Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. Cardiovasc Res, 57:225–231. 2003.
7.
AhmedZ, RavandiA, MaguireGF, EmiliA, DraganovD, La DuBN, KuksisA, ConnellyPW. Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem Biophys Res Commun, 290:391–396. 2002.
8.
AksoyN, AksoyM, BagciC, GergerliogluHS, CelikH, HerkenE, YamanA, TarakciogluM, SoydincS, SariI, DavutogluV. Pistachio intake increases high density lipoprotein levels and inhibits low-density lipoprotein oxidation in rats. Tohoku J Exp Med, 212:43–48. 2007.
9.
AldridgeWN. Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem J, 53:110–117. 1953.
10.
AldridgeWN. Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J, 53:117–124. 1953.
11.
AltenhoferS, WitteI, TeiberJF, WilgenbusP, PautzA, LiH, DaiberA, WitanH, ClementAM, ForstermannU, HorkeS. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J Biol Chem, 285:24398–24403. 2010.
12.
AntoniadesC, AntonopoulosAS, TousoulisD, MarinouK, StefanadisC. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J, 30:6–15. 2009.
13.
AntoniadesC, ShirodariaC, WarrickN, CaiS, de BonoJ, LeeJ, LeesonP, NeubauerS, RatnatungaC, PillaiR, RefsumH, ChannonKM. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation, 114:1193–1201. 2006.
14.
ArcaM, OmbresD, MontaliA, CampagnaF, MangieriE, TanzilliG, CampaPP, RicciG, VernaR, PannitteriG. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest, 32:9–15. 2002.
15.
ArgmannCA, SawyezCG, LiS, NongZ, HegeleRA, PickeringJG, HuffMW. Human smooth muscle cell subpopulations differentially accumulate cholesteryl ester when exposed to native and oxidized lipoproteins. Arterioscler Thromb Vasc Biol, 24:1290–1296. 2004.
16.
AriiK, SuehiroT, IkedaY, KumonY, InoueM, InadaS, TakataH, IshibashiA, HashimotoK, TeradaY. Role of protein kinase C in pitavastatin-induced human paraoxonase I expression in Huh7 cells. Metabolism, 59:1287–1293. 2010.
17.
AriiK, SuehiroT, OtaK, IkedaY, KumonY, OsakiF, InoueM, InadaS, OgamiN, TakataH, HashimotoK, TeradaY. Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis, 202:439–445. 2009.
AutioI, JaakkolaO, SolakiviT, NikkariT. Oxidized low-density lipoprotein is chemotactic for arterial smooth muscle cells in culture. FEBS Lett, 277:247–249. 1990.
20.
AviramM. Does paraoxonase play a role in susceptibility to cardiovascular disease?Mol Med Today, 5:381–386. 1999.
21.
AviramM, BilleckeS, SorensonR, BisgaierC, NewtonR, RosenblatM, ErogulJ, HsuC, DunlopC, La DuB. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol, 18:1617–1624. 1998.
22.
AviramM, HardakE, VayaJ, MahmoodS, MiloS, HoffmanA, BillickeS, DraganovD, RosenblatM. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation, 101:2510–2517. 2000.
23.
AviramM, RosenblatM. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med, 37:1304–1316. 2004.
24.
AviramM, RosenblatM. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol, 16:393–399. 2005.
25.
AviramM, RosenblatM, BilleckeS, ErogulJ, SorensonR, BisgaierCL, NewtonRS, La DuB. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med, 26:892–904. 1999.
26.
AviramM, RosenblatM, BisgaierCL, NewtonRS, Primo-ParmoSL, La DuBN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest, 101:1581–1590. 1998.
BaloghZ, SeresI, HarangiM, KovacsP, KakukG, ParaghG. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?Diabetes Metab, 27:604–610. 2001.
30.
BaoXM, WuCF, LuGP. Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis, 210:114–121. 2010.
31.
BarbieriM, BonafeM, MarfellaR, RagnoE, GiuglianoD, FranceschiC, PaolissoG. LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. J Clin Endocrinol Metab, 87:222–225. 2002.
32.
BarterP, GottoAM, LaRosaJC, MaroniJ, SzarekM, GrundySM, KasteleinJJ, BittnerV, FruchartJC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 357:1301–1310. 2007.
BearM, ButcherM, ShaughnessySG. Oxidized low-density lipoprotein acts synergistically with beta-glycerophosphate to induce osteoblast differentiation in primary cultures of vascular smooth muscle cells. J Cell Biochem, 105:185–193. 2008.
35.
BellasRE, HarringtonEO, SheahanKL, NewtonJ, MarcusC, RoundsS. FAK blunts adenosine-homocysteine-induced endothelial cell apoptosis: requirement for PI 3-kinase. Am J Physiol Lung Cell Mol Physiol, 282:L1135–L1142. 2002.
36.
BeltowskiJ, WojcickaG, JakubowskiH. Modulation of paraoxonase 1 and protein N-homocysteinylation by leptin and the synthetic liver X receptor agonist T0901317 in the rat. J Endocrinol, 204:191–198. 2010.
37.
BeltowskiJ, WojcickaG, JamrozA. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis, 170:21–29. 2003.
38.
BhattacharyyaT, NichollsSJ, TopolEJ, ZhangR, YangX, SchmittD, FuX, ShaoM, BrennanDM, EllisSG, BrennanML, AllayeeH, LusisAJ, HazenSL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA, 299:1265–1276. 2008.
39.
BienvenuT, AnkriA, ChadefauxB, MontalescotG, KamounP. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res, 70:123–129. 1993.
40.
BiggadikeK, AngellRM, BurgessCM, FarrellRM, HancockAP, HarkerAJ, IrvingWR, IoannouC, ProcopiouPA, ShawRE, SolankeYE, SinghOM, SnowdenMA, StubbsRJ, WaltonS, WestonHE. Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J Med Chem, 43:19–21. 2000.
41.
BilleckeS, DraganovD, CounsellR, StetsonP, WatsonC, HsuC, La DuBN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos, 28:1335–1342. 2000.
42.
BinderCJ, ChangMK, ShawPX, MillerYI, HartvigsenK, DewanA, WitztumJL. Innate and acquired immunity in atherogenesis. Nat Med, 8:1218–1226. 2002.
43.
Blatter-GarinMC, KalixB, De PreeS, JamesRW. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia, 46:593–594. 2003.
44.
Boesch-SaadatmandiC, EgertS, SchraderC, CoumoulX, BaroukiR, MullerMJ, WolfframS, RimbachG. Effect of quercetin on paraoxonase 1 activity—studies in cultured cells, mice and humans. J Physiol Pharmacol, 61:99–105. 2010.
45.
Boesch-SaadatmandiC, NieringJ, MinihaneAM, WiswedelI, GardemanA, WolfframS, RimbachG. Impact of apolipoprotein E genotype and dietary quercetin on paraoxonase 1 status in apoE3 and apoE4 transgenic mice. Atherosclerosis, 211:110–113. 2010.
46.
Boesch-SaadatmandiC, PospissilRT, GraeserAC, CanaliR, BoomgaardenI, DoeringF, WolfframS, EgertS, MuellerMJ, RimbachG. Effect of quercetin on paraoxonase 2 levels in RAW264.7 macrophages and in human monocytes—role of quercetin metabolism. Int J Mol Sci, 10:4168–4177. 2009.
47.
BonafeM, MarchegianiF, CardelliM, OlivieriF, CavalloneL, GiovagnettiS, PieriC, MarraM, AntonicelliR, TroianoL, GueresiP, PasseriG, BerardelliM, PaolissoG, BarbieriM, TeseiS, LisaR, De BenedictisG, FranceschiC. Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur J Hum Genet, 10:292–296. 2002.
48.
BorightAP, ConnellyPW, BruntJH, SchererSW, TsuiLC, HegeleRA. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis, 139:131–136. 1998.
49.
BousheyCJ, BeresfordSA, OmennGS, MotulskyAG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA, 274:1049–1057. 1995.
50.
BowersJL, TyulmenkovVV, JerniganSC, KlingeCM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology, 141:3657–3667. 2000.
51.
BrattstromL, WilckenDE. Homocysteine and cardiovascular disease: cause or effect?Am J Clin Nutr, 72:315–323. 2000.
52.
BraunwaldE. Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med, 337:1360–1369. 1997.
53.
BrewerHBJr.Increasing HDL Cholesterol Levels. N Engl J Med, 350:1491–1494. 2004.
54.
BrophyVH, HastingsMD, ClendenningJB, RichterRJ, JarvikGP, FurlongCE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics, 11:77–84. 2001.
55.
BrophyVH, JampsaRL, ClendenningJB, McKinstryLA, JarvikGP, FurlongCE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet, 68:1428–1436. 2001.
56.
CaliebeA, KleindorpR, BlancheH, ChristiansenL, PucaAA, ReaIM, SlagboomE, FlachsbartF, ChristensenK, RimbachG, SchreiberS, NebelA. No or only population-specific effect of PON1 on human longevity: a comprehensive meta-analysis. Ageing Res Rev, 9:238–244. 2010.
57.
CampsJ, MarsillachJ, JovenJ. Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. Mini Rev Med Chem, 9:911–920. 2009.
58.
CardenasGA, LavieCJ, CardenasV, MilaniRV, McCulloughPA. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med, 9:239–258. 2008.
59.
CarluccioMA, SiculellaL, AncoraMA, MassaroM, ScodittiE, StorelliC, VisioliF, DistanteA, De CaterinaR. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol, 23:622–629. 2003.
60.
Carreon-TorresE, Rendon-SauerK, Monter-GarridoM, Toledo-IbellesP, GamboaR, MenjivarM, Lopez-MarureR, LucG, FievetC, CruzD, Vargas-AlarconG, Perez-MendezO. Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates. Clin Chim Acta, 401:37–41. 2009.
61.
CasperRF, QuesneM, RogersIM, ShirotaT, JolivetA, MilgromE, SavouretJF. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol, 56:784–790. 1999.
62.
ChaiYC, HowePH, DiCorletoPE, ChisolmGM. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J Biol Chem, 271:17791–17797. 1996.
63.
ChenC, HalkosME, SurowiecSM, ConklinBS, LinPH, LumsdenAB. Effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models. J Surg Res, 88:26–33. 2000.
64.
ChenJ, MehtaJL, HaiderN, ZhangX, NarulaJ, LiD. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res, 94:370–376. 2004.
65.
ChenQ, ReisSE, KammererCM, McNamaraDM, HolubkovR, SharafBL, SopkoG, PaulyDF, MerzCN, KambohMI. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet, 72:13–22. 2003.
66.
CherkiM, BerrouguiH, IsabelleM, CloutierM, KoumbadingaGA, KhalilA. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. Exp Gerontol, 42:815–824. 2007.
67.
ChristenWG, AjaniUA, GlynnRJ, HennekensCH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual?Arch Intern Med, 160:422–434. 2000.
68.
ColeTB, JampsaRL, WalterBJ, ArndtTL, RichterRJ, ShihDM, TwardA, LusisAJ, JackRM, CostaLG, FurlongCE. Expression of human paraoxonase (PON1) during development. Pharmacogenetics, 13:357–364. 2003.
69.
CollesSM, MaxsonJM, CarlsonSG, ChisolmGM. Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols. Trends Cardiovasc Med, 11:131–138. 2001.
70.
CominaciniL, GarbinU, PasiniAF, DavoliA, CampagnolaM, ContessiGB, PastorinoAM, Lo CascioV. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med, 22:117–127. 1997.
71.
CominaciniL, PasiniAF, GarbinU, DavoliA, TosettiML, CampagnolaM, RigoniA, PastorinoAM, Lo CascioV, SawamuraT. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem, 275:12633–12638. 2000.
72.
ConnellyPW, DraganovD, MaguireGF. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic Biol Med, 38:164–174. 2005.
73.
CostaLG, ColeTB, JarvikGP, FurlongCE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med, 54:371–392. 2003.
74.
CostaLG, GiordanoG, FurlongCE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol, 81:337–344. 2011.
CuiMZ, PennMS, ChisolmGM. Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. J Biol Chem, 274:32795–32802. 1999.
77.
CushingSD, BerlinerJA, ValenteAJ, TerritoMC, NavabM, ParhamiF, GerrityR, SchwartzCJ, FogelmanAM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A, 87:5134–5138. 1990.
78.
DaviesHG, RichterRJ, KeiferM, BroomfieldCA, SowallaJ, FurlongCE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet, 14:334–336. 1996.
79.
De GeestB, StengelD, LandeloosM, LoxM, Le GatL, CollenD, HolvoetP, NinioE. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler Thromb Vasc Biol, 20:E68–E75. 2000.
80.
DeakinS, LevievI, Brulhart-MeynetMC, JamesRW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position −107, implicating the Sp1 transcription factor. Biochem J, 372:643–649. 2003.
81.
DeakinS, LevievI, GomaraschiM, CalabresiL, FranceschiniG, JamesRW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem, 277:4301–4308. 2002.
82.
DeakinS, LevievI, GuernierS, JamesRW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol, 23:2083–2089. 2003.
83.
DevarajanA, BourquardN, HamaS, NavabM, GrijalvaVR, MorvardiS, ClarkeCF, VergnesL, ReueK, TeiberJF, ReddyST. Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid Redox Signal, 14:341–351. 2011.
84.
DorupI, SorensenKE. [Non-invasive assessment of endothelial function]Ugeskr Laeger, 160:3376–3382. 1998.
85.
DraganovDI, La DuBN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol, 369:78–88. 2004.
86.
DraganovDI, StetsonPL, WatsonCE, BilleckeSS, La DuBN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem, 275:33435–33442. 2000.
87.
DraganovDI, TeiberJF, SpeelmanA, OsawaY, SunaharaR, La DuBN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res, 46:1239–1247. 2005.
88.
DullaartRP, de VriesR, SluiterWJ, VoorbijHA. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin Endocrinol (Oxf ), 70:221–226. 2009.
DurringtonPN, MacknessMI, BhatnagarD, JulierK, PraisH, ArrolS, MorganJ, WoodGN. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis, 138:217–225. 1998.
91.
EsslerM, RetzerM, BauerM, HeemskerkJW, AepfelbacherM, SiessW. Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem, 274:30361–30364. 1999.
92.
FanellaS, HarrisSB, YoungTK, HanleyAJ, ZinmanB, ConnellyPW, HegeleRA. Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin Chem Lab Med, 38:413–420. 2000.
93.
FengJ, HanJ, PearceSF, SilversteinRL, GottoAMJr., HajjarDP, NicholsonAC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res, 41:688–696. 2000.
94.
FenkciIV, SerteserM, FenkciS, AkyolAM. Effects of intranasal estradiol treatment on serum paraoxonase and lipids in healthy, postmenopausal women. Gynecol Obstet Invest, 61:203–207. 2006.
95.
FerrettiG, BacchettiT, MasciangeloS, BicchiegaV. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring), 18:1079–1084. 2010.
96.
FerrettiG, BacchettiT, MoroniC, SavinoS, LiuzziA, BalzolaF, BicchiegaV. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab, 90:1728–1733. 2005.
97.
FlekacM, SkrhaJ, ZidkovaK, LacinovaZ, HilgertovaJ. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res, 57:717–726. 2008.
98.
FryerRH, WilsonBD, GublerDB, FitzgeraldLA, RodgersGM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb, 13:1327–1333. 1993.
99.
FuhrmanB, GantmanA, KhateebJ, VolkovaN, HorkeS, KiyanJ, DumlerI, AviramM. Urokinase activates macrophage PON2 gene transcription via the PI3K/ROS/MEK/SREBP-2 signalling cascade mediated by the PDGFR-beta. Cardiovasc Res, 84:145–154. 2009.
100.
FuhrmanB, KhateebJ, ShinerM, NitzanO, KarryR, VolkovaN, AviramM. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism. Arterioscler Thromb Vasc Biol, 28:1361–1367. 2008.
101.
FurlongCE, ColeTB, JarvikGP, CostaLG. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics, 3:341–348. 2002.
102.
GarinMC, KalixB, MorabiaA, JamesRW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab, 90:2264–2269. 2005.
103.
GhorbanihaghjoA, ArganiH, RahbaninoubarM, RashtchizadehN. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients. Clin Biochem, 38:1076–1080. 2005.
104.
GinsbergG, NeafseyP, HattisD, GuytonKZ, JohnsDO, SonawaneB. Genetic polymorphism in paraoxonase 1 (PON1): population distribution of PON1 activity. J Toxicol Environ Health B Crit Rev, 12:473–507. 2009.
105.
GlassCK, WitztumJL. Atherosclerosis. the road ahead. Cell, 104:503–516. 2001.
GottoAMJr.and Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol, 43:717–724. 2004.
110.
GottoAMJr., PownallHJ, HavelRJ. Introduction to the plasma lipoproteins. Methods Enzymol, 128:3–41. 1986.
111.
GouedardC, BaroukiR, MorelY. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol, 24:2378–2383. 2004.
GouedardC, Koum-BessonN, BaroukiR, MorelY. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol, 63:945–956. 2003.
114.
GrundySM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol, 83:25F–29F. 1999.
115.
GugliucciA, LuncefordN, KinugasaE, OgataH, SchulzeJ, KimuraS. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta, 384:105–112. 2007.
116.
GusmanJ, MalonneH, AtassiG. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis, 22:1111–1117. 2001.
117.
HameletJ, Ait-Yahya-GraisonE, MatulewiczE, NollC, Badel-ChagnonA, CamprouxAC, DemuthK, PaulJL, DelabarJM, JanelN. Homocysteine threshold value based on cystathionine beta synthase and paraoxonase 1 activities in mice. Eur J Clin Invest, 37:933–938. 2007.
118.
HanJ, HajjarDP, FebbraioM, NicholsonAC. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem, 272:21654–21659. 1997.
119.
HarangiM, SeresI, VargaZ, EmriG, SzilvassyZ, ParaghG, RemenyikE. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol, 60:685–691. 2004.
120.
HarelM, AharoniA, GaidukovL, BrumshteinB, KhersonskyO, MegedR, DvirH, RavelliRB, McCarthyA, TokerL, SilmanI, SussmanJL, TawfikDS. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol, 11:412–419. 2004.
121.
HarkerLA, SlichterSJ, ScottCR, RossR. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med, 291:537–543. 1974.
122.
HarmanD. Aging: a theory based on free radical and radiation chemistry. J Gerontol, 11:298–300. 1956.
123.
HarpelPC, ZhangX, BorthW. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr, 126:1285S–1289S. 1996.
124.
HassettC, RichterRJ, HumbertR, ChaplineC, CrabbJW, OmiecinskiCJ, FurlongCE. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry, 30:10141–10149. 1991.
125.
HeF, GuoR, WuSL, SunM, LiM. Protective effects of ginsenoside Rb1 on human umbilical vein endothelial cells in vitro. J Cardiovasc Pharmacol, 50:314–320. 2007.
HegeleRA. Paraoxonase genes and disease. Ann Med, 31:217–224. 1999.
128.
HeineckeJW, LusisAJ. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis?Am J Hum Genet, 62:20–24. 1998.
HesslerJR, RobertsonALJr., ChisolmGM3rd. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis, 32:213–229. 1979.
131.
Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 288:2015–2022. 2002.
132.
HongSC, ZhaoSP, WuZH. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol, 47:77–81. 2006.
133.
HorkeS, WitteI, AltenhoferS, WilgenbusP, GoldeckM, ForstermannU, XiaoJ, KramerGL, HainesDC, ChowdharyPK, HaleyRW, TeiberJF. Paraoxonase 2 is down-regulated by the Pseudomonas aeruginosa quorumsensing signal N-(3-oxododecanoyl)-L-homoserine lactone and attenuates oxidative stress induced by pyocyanin. Biochem J, 426:73–83. 2010.
HumbertR, AdlerDA, DistecheCM, HassettC, OmiecinskiCJ, FurlongCE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet, 3:73–76. 1993.
136.
HundalRS, SalhBS, SchraderJW, Gomez-MunozA, DuronioV, SteinbrecherUP. Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI 3-kinase/PKB pathway. J Lipid Res, 42:1483–1491. 2001.
137.
IkedaT, ObayashiH, HasegawaG, NakamuraN, YoshikawaT, ImamuraY, KoizumiK, KinoshitaS. Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. Am J Ophthalmol, 132:191–195. 2001.
138.
IkedaY, InoueM, SuehiroT, AriiK, KumonY, HashimotoK. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol, 46:239–242. 2009.
139.
IkedaY, SuehiroT, InoueM, NakauchiY, MoritaT, AriiK, ItoH, KumonY, HashimotoK. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism, 47:598–602. 1998.
140.
ImaiY, MoritaH, KuriharaH, SugiyamaT, KatoN, EbiharaA, HamadaC, KuriharaY, ShindoT, Oh-hashiY, YazakiY. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis, 149:435–442. 2000.
IwashimaY, EtoM, HataA, KakuK, HoriuchiS, UshikubiF, SanoH. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun, 277:368–380. 2000.
144.
JaichanderP, SelvarajanK, GarelnabiM, ParthasarathyS. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res, 49:2142–2148. 2008.
145.
JakubowskiH. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem, 275:3957–3962. 2000.
146.
JakubowskiH. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol, 59,Suppl 9:155–167. 2008.
147.
JakubowskiH. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv Exp Med Biol, 660:113–127. 2010.
148.
JakubowskiH, AmbrosiusWT, PrattJH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett, 491:35–39. 2001.
149.
JakubowskiH, ZhangL, BardeguezA, AvivA. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res, 87:45–51. 2000.
150.
JamesRW, Blatter GarinMC, CalabresiL, MiccoliR, von EckardsteinA, Tilly-KiesiM, TaskinenMR, AssmannG, FranceschiniG. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis, 139:77–82. 1998.
151.
JamesRW, LevievI, RighettiA. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation, 101:2252–2257. 2000.
152.
JamesRW, LevievI, RuizJ, PassaP, FroguelP, GarinMC. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes, 49:1390–1393. 2000.
153.
JaouadL, de GuiseC, BerrouguiH, CloutierM, IsabelleM, FulopT, PayetteH, KhalilA. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis, 185:191–200. 2006.
154.
JarvikGP, RozekLS, BrophyVH, HatsukamiTS, RichterRJ, SchellenbergGD, FurlongCE. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol, 20:2441–2447. 2000.
155.
JarvikGP, TsaiNT, McKinstryLA, WaniR, BrophyVH, RichterRJ, SchellenbergGD, HeagertyPJ, HatsukamiTS, FurlongCE. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol, 22:1329–1333. 2002.
156.
JeonSM, ParkYB, KwonOS, HuhTL, LeeWH, DoKM, ParkT, ChoiMS. Vitamin E supplementation alters HDL-cholesterol concentration and paraoxonase activity in rabbits fed high-cholesterol diet: comparison with probucol. J Biochem Mol Toxicol, 19:336–346. 2005.
157.
JiangC, ZhangH, ZhangW, KongW, ZhuY, XuQ, LiY, WangX. Homocysteine promotes vascular smooth muscle cell migration by induction of the adipokine resistin. Am J Physiol Cell Physiol, 297:C1466–C1476. 2009.
158.
JiangH, WangXF, FangL, TangC, ZhuY, WangX. Upregulation of aldose reductase by homocysteine in type II alveolar epithelial cells. Biochem Biophys Res Commun, 337:1084–1091. 2005.
159.
JimiS, SakuK, UesugiN, SakataN, TakebayashiS. Oxidized low density lipoprotein stimulates collagen production in cultured arterial smooth muscle cells. Atherosclerosis, 116:15–26. 1995.
160.
JosseD, XieW, MassonP, LockridgeO. Human serum paraoxonase (PON1): identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis. Chem Biol Interact, 119–12071–781999.
161.
JosseD, XieW, RenaultF, RochuD, SchopferLM, MassonP, LockridgeO. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry, 38:2816–2825. 1999.
162.
KaoYL, DonaghueK, ChanA, KnightJ, SilinkM. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab, 83:2589–2592. 1998.
163.
KarikasGA, KriebardisA, SamaraI, SchulpisK, PapachristodoulouM, Fytou-PallikariA. Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece. Clin Chem Lab Med, 44:623–627. 2006.
164.
KassaiA, IllyesL, MirdamadiHZ, SeresI, KalmarT, AudikovszkyM, ParaghG. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem, 40:1–5. 2007.
165.
KerkeniM, AddadF, ChauffertM, ChuniaudL, MiledA, TrivinF, MaaroufiK. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem, 39:821–825. 2006.
166.
KhanM, PelengarisS, CooperM, SmithC, EvanG, BetteridgeJ. Oxidised lipoproteins may promote inflammation through the selective delay of engulfment but not binding of apoptotic cells by macrophages. Atherosclerosis, 171:21–29. 2003.
167.
KhersonskyO, TawfikDS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry, 44:6371–6382. 2005.
168.
KiranogluS, SinanS, GencerN, KockarF, ArslanO. In vivo effects of oral contraceptives on paraoxonase, catalase and carbonic anhydrase enzyme activities on mouse. Biol Pharm Bull, 30:1048–1051. 2007.
169.
KobayashiM, ShinoharaM, SakohC, KataokaM, ShimizuS. Lactone-ring-cleaving enzyme: genetic analysis, novel RNA editing, and evolutionary implications. Proc Natl Acad Sci U S A, 95:12787–12792. 1998.
170.
KoncsosP, SeresI, HarangiM, IllyesI, JozsaL, GoncziF, BajnokL, ParaghG. Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels. Pediatr Res, 67:309–313. 2010.
171.
KordonouriO, JamesRW, BennettsB, ChanA, KaoYL, DanneT, SilinkM, DonaghueK. Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism, 50:657–660. 2001.
172.
KosakaT, YamaguchiM, MotomuraT, MizunoK. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta, 359:156–162. 2005.
173.
KosugiK, MorelDW, DiCorletoPE, ChisolmGM. Toxicity of oxidized low-density lipoprotein to cultured fibroblasts is selective for S phase of the cell cycle. J Cell Physiol, 130:311–320. 1987.
KumonY, SuehiroT, IkedaY, HashimotoK. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci, 73:2807–2815. 2003.
176.
KumruS, AydinS, ArasA, GursuMF, GulcuF. Effects of surgical menopause and estrogen replacement therapy on serum paraoxonase activity and plasma malondialdehyde concentration. Gynecol Obstet Invest, 59:108–112. 2005.
177.
KunesJP, Cordero-KoningKS, LeeLH, LynchSM. Vitamin C attenuates hypochlorite-mediated loss of paraoxonase-1 activity from human plasma. Nutr Res, 29:114–122. 2009.
178.
KuoCL, La DuBN. Comparison of purified human and rabbit serum paraoxonases. Drug Metab Dispos, 23:935–944. 1995.
179.
KuoCL, La DuBN. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab Dispos, 26:653–660. 1998.
180.
KurbanS, MehmetogluI. Effects of acetylsalicylic acid on serum paraoxonase activity, Ox-LDL, coenzyme Q10 and other oxidative stress markers in healthy volunteers. Clin Biochem, 43:287–290. 2010.
181.
La DuBN. Structural and functional diversity of paraoxonases. Nat Med, 2:1186–1187. 1996.
182.
LacinskiM, SkorupskiW, CieslinskiA, SokolowskaJ, TrzeciakWH, JakubowskiH. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol (Noisy-le-grand), 50:885–893. 2004.
183.
LafontAM, ChaiYC, CornhillJF, WhitlowPL, HowePH, ChisolmGM. Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis. J Clin Invest, 95:1018–1025. 1995.
184.
LagosKG, FilippatosTD, TsimihodimosV, GaziIF, RizosC, TselepisAD, MikhailidisDP, ElisafMS. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids, 44:9–16. 2009.
185.
LakshmanMR, GottipatiCS, NarasimhanSJ, MunozJ, MarmillotP, NylenES. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism, 55:1201–1206. 2006.
186.
LeckeyLC, GarigeM, VaratharajaluR, GongM, NagataT, SpurneyCF, LakshmanRM. Quercetin and ethanol attenuate the progression of atherosclerotic plaques with concomitant up regulation of paraoxonase1 (PON1) gene expression and PON1 activity in LDLR-/- mice. Alcohol Clin Exp Res, 34:1535–1542. 2010.
187.
LeeJM, ChoudhuryRP. Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart, 93:559–564. 2007.
188.
LeeSJ, KimKM, NamkoongS, KimCK, KangYC, LeeH, HaKS, HanJA, ChungHT, KwonYG, KimYM. Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem, 280:5781–5788. 2005.
189.
LeusFR, ZwartM, KasteleinJJ, VoorbijHA. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis, 154:641–649. 2001.
190.
LevievI, JamesRW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol, 20:516–521. 2000.
191.
LevievI, KalixB, Brulhart MeynetMC, JamesRW. The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia, 44:1177–1183. 2001.
192.
LevievI, NegroF, JamesRW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol, 17:2935–2939. 1997.
193.
LevievI, PoirierO, NicaudV, EvansA, KeeF, ArveilerD, MorrissonC, CambienF, JamesRW. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis, 161:463–467. 2002.
194.
LevievI, RighettiA, JamesRW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med, 79:457–463. 2001.
195.
LiD, MehtaJL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol, 20:1116–1122. 2000.
LusisAJ, FogelmanAM, FonarowGC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation, 110:1868–1873. 2004.
204.
MacknessB, DaviesGK, TurkieW, LeeE, RobertsDH, HillE, RobertsC, DurringtonPN, MacknessMI. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?Arterioscler Thromb Vasc Biol, 21:1451–1457. 2001.
MacknessB, DurringtonPN, MacknessMI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol, 13:357–362. 2002.
207.
MacknessB, McElduffP, MacknessMI. The paraoxonase-2–310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus. J Intern Med, 258:363–368. 2005.
208.
MacknessB, QuarckR, VerrethW, MacknessM, HolvoetP. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol, 26:1545–1550. 2006.
209.
MacknessMI, ArrolS, DurringtonPN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett, 286:152–154. 1991.
MacpheeCH, NelsonJJ, ZalewskiA. Lipoprotein-associated phospholipase A2 as a target of therapy. Curr Opin Lipidol, 16:442–446. 2005.
212.
MaierJA, BarenghiL, PaganiF, BradamanteS, ComiP, RagnottiG. The protective role of high-density lipoprotein on oxidized-low-density-lipoprotein-induced U937/endothelial cell interactions. Eur J Biochem, 221:35–41. 1994.
213.
MajorsA, EhrhartLA, PezackaEH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol, 17:2074–2081. 1997.
214.
MalinR, KnuutiJ, JanatuinenT, LaaksonenR, VesalainenR, NuutilaP, JokelaH, LaaksoJ, JaakkolaO, SolakiviT, LehtimakiT. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med, 79:449–458. 2001.
215.
MalinR, LaaksonenR, KnuutiJ, JanatuinenT, VesalainenR, NuutilaP, LehtimakiT. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics, 11:625–633. 2001.
216.
MaratheGK, ZimmermanGA, McIntyreTM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem, 278:3937–3947. 2003.
217.
MarchegianiF, MarraM, SpazzafumoL, JamesRW, BoemiM, OlivieriF, CardelliM, CavalloneL, BonfigliAR, FranceschiC. Paraoxonase activity and genotype predispose to successful aging. J Gerontol A Biol Sci Med Sci, 61:541–546. 2006.
218.
MarinouK, AntoniadesC, TousoulisD, PitsavosC, GoumasG, StefanadisC. Homocysteine: a risk factor for coronary artery disease?Hellenic J Cardiol, 46:59–67. 2005.
219.
MaritimAC, SandersRA, WatkinsJB3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol, 17:24–38. 2003.
MarsillachJ, Martinez-VeaA, MarcasL, MacknessB, MacknessM, FerreN, JovenJ, CampsJ. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin Exp Pharmacol Physiol, 34:347–349. 2007.
222.
MartensJS, LougheedM, Gomez-MunozA, SteinbrecherUP. A modification of apolipoprotein B accounts for most of the induction of macrophage growth by oxidized low density lipoprotein. J Biol Chem, 274:10903–10910. 1999.
223.
MartensJS, ReinerNE, Herrera-VelitP, SteinbrecherUP. Phosphatidylinositol 3-kinase is involved in the induction of macrophage growth by oxidized low density lipoprotein. J Biol Chem, 273:4915–4920. 1998.
224.
MartinelliN, GirelliD, OlivieriO, CavallariU, BiscuolaM, TrabettiE, FrisoS, PizzoloF, TenutiI, BozziniC, VillaG, CeradiniB, SandriM, ChengS, GrowMA, PignattiPF, CorrocherR. Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease. Clin Exp Med, 5:20–30. 2005.
225.
MartinetW, KockxMM. Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation. Curr Opin Lipidol, 12:535–541. 2001.
226.
MaziereC, Djavaheri-MergnyM, Frey-FressartV, DelattreJ, MaziereJC. Copper and cell-oxidized low-density lipoprotein induces activator protein 1 in fibroblasts, endothelial and smooth muscle cells. FEBS Lett, 409:351–356. 1997.
227.
MazurA. An enzyme in animal tissues capable of hydrolyze the phosphorus-fluorine bond of alkyl fluorophosphates. J Biol Chem, 164:271–289. 1946.
228.
McCullyKS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol, 56:111–128. 1969.
229.
McDonaldL, BrayC, FieldC, LoveF, DaviesB. Homocystinuria, Thrombosis, and the Blood-Platelets. Lancet, 1:745–746. 1964.
230.
MertensA, HolvoetP. Oxidized LDL and HDL: antagonists in atherothrombosis. Faseb J, 15:2073–2084. 2001.
231.
MeyeC, SchumannJ, WagnerA, GrossP. Effects of homocysteine on the levels of caveolin-1 and eNOS in caveolae of human coronary artery endothelial cells. Atherosclerosis, 190:256–263. 2007.
232.
MilochevitchC, KhalilA. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot Essent Fatty Acids, 65:241–246. 2001.
233.
MiuraD, MiuraY, YagasakiK. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci, 73:1393–1400. 2003.
234.
MochizukiH, SchererSW, XiT, NickleDC, MajerM, HuizengaJJ, TsuiLC, ProchazkaM. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene, 213:149–157. 1998.
235.
MurataM, MaruyamaT, SuzukiY, SarutaT, IkedaY. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet Med, 21:837–844. 2004.
236.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106:3143–3421. 2002.
237.
NavabM, AnanthramaiahGM, ReddyST, Van LentenBJ, AnsellBJ, FonarowGC, VahabzadehK, HamaS, HoughG, KamranpourN, BerlinerJA, LusisAJ, FogelmanAM. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res, 45:993–1007. 2004.
238.
NavabM, BerlinerJA, SubbanagounderG, HamaS, LusisAJ, CastellaniLW, ReddyS, ShihD, ShiW, WatsonAD, Van LentenBJ, VoraD, FogelmanAM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol, 21:481–488. 2001.
239.
NavabM, Hama-LevyS, Van LentenBJ, FonarowGC, CardinezCJ, CastellaniLW, BrennanML, LusisAJ, FogelmanAM, La DuBN. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest, 99:2005–2019. 1997.
240.
Negre-SalvayreA, LopezM, LevadeT, PieraggiMT, DoussetN, Douste-BlazyL, SalvayreR. Ultraviolet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. II. Uptake and cytotoxicity of ultraviolet-treated LDL on lymphoid cell lines. Biochim Biophys Acta, 1045:224–232. 1990.
241.
NevadoJBJr., ImasaMS. Homocysteine predicts adverse clinical outcomes in unstable angina and non-ST elevation myocardial infarction: implications from the folate intervention in non-ST elevation myocardial infarction and unstable angina study. Coron Artery Dis, 19:153–161. 2008.
242.
NgCJ, BourquardN, GrijalvaV, HamaS, ShihDM, NavabM, FogelmanAM, LusisAJ, YoungS, ReddyST. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem, 281:29491–29500. 2006.
243.
NgCJ, BourquardN, HamaSY, ShihD, GrijalvaVR, NavabM, FogelmanAM, ReddyST. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 27:1368–1374. 2007.
244.
NgCJ, HamaSY, BourquardN, NavabM, ReddyST. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol Genet Metab, 89:368–373. 2006.
245.
NgCJ, ShihDM, HamaSY, VillaN, NavabM, ReddyST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med, 38:153–163. 2005.
246.
NgCJ, WadleighDJ, GangopadhyayA, HamaS, GrijalvaVR, NavabM, FogelmanAM, ReddyST. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem, 276:44444–44449. 2001.
247.
NicholsonAC, HajjarDP. CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis. Vascul Pharmacol, 41:139–146. 2004.
248.
NishioE, WatanabeY. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun, 236:289–293. 1997.
249.
NollC, HameletJ, MatulewiczE, PaulJL, DelabarJM, JanelN. Effects of red wine polyphenolic compounds on paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in hyperhomocysteinemic mice. J Nutr Biochem, 20:586–596. 2009.
250.
NollC, MessaoudiS, MilliezP, SamuelJL, DelcayreC, JanelN. Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice. Atherosclerosis, 208:26–27. 2010.
251.
OdaMN, BielickiJK, HoTT, BergerT, RubinEM, ForteTM. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun, 290:921–927. 2002.
252.
OkuraY, BrinkM, ItabeH, ScheideggerKJ, KalangosA, DelafontaineP. Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. Circulation, 102:2680–2686. 2000.
253.
OsakiF, IkedaY, SuehiroT, OtaK, TsuzuraS, AriiK, KumonY, HashimotoK. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis, 176:279–287. 2004.
254.
Osei-HyiamanD, HouL, MengbaiF, ZhiyinR, ZhimingZ, KanoK. Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraxonase 1 gene (Q192R) polymorphism?Eur J Endocrinol, 144:639–644. 2001.
255.
OzolsJ. Isolation and complete covalent structure of liver microsomal paraoxonase. Biochem J, 338,Pt 2:265–272. 1999.
256.
PanJP, LaiST, ChiangSC, ChouSC, ChiangAN. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei), 65:415–421. 2002.
PaoliP, SbranaF, TiribilliB, CaselliA, PanteraB, CirriP, De DonatisA, FormigliL, NosiD, ManaoG, CamiciG, RamponiG. Protein N-homocysteinylation induces the formation of toxic amyloid-like protofibrils. J Mol Biol, 400:889–907. 2010.
259.
PaolissoG, TagliamonteMR, RizzoMR, GiuglianoD. Advancing age and insulin resistance: new facts about an ancient history. Eur J Clin Invest, 29:758–769. 1999.
260.
ParaghG, SeresI, HarangiM, BaloghZ, IllyesL, BodaJ, SzilvassyZ, KovacsP. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. Diabetes Metab, 29:613–618. 2003.
ParaghG, TorocsikD, SeresI, HarangiM, IllyesL, BaloghZ, KovacsP. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin, 20:1321–1327. 2004.
263.
ParkSA, ChoiMS, JungUJ, KimMJ, KimDJ, ParkHM, ParkYB, LeeMK. Eucommia ulmoides Oliver leaf extract increases endogenous antioxidant activity in type 2 diabetic mice. J Med Food, 9:474–479. 2006.
264.
Perla-KajanJ, JakubowskiH. Paraoxonase 1 protects against protein N-homocysteinylation in humans. Faseb J, 24:931–936. 2010.
265.
Perla-KajanJ, StangerO, LuczakM, ZiolkowskaA, MalendowiczLK, TwardowskiT, LhotakS, AustinRC, JakubowskiH. Immunohistochemical detection of N-homocysteinylated proteins in humans and mice. Biomed Pharmacother, 62:473–479. 2008.
266.
PervaizS. Resveratrol: from grapevines to mammalian biology. Faseb J, 17:1975–1985. 2003.
267.
PinizzottoM, CastilloE, FiauxM, TemlerE, GaillardRC, RuizJ. Paraoxonase2 polymorphisms are associated with nephropathy in Type II diabetes. Diabetologia, 44:104–107. 2001.
268.
PrecourtLP, SeidmanE, DelvinE, AmreD, DeslandresC, DominguezM, SinnettD, LevyE. Comparative expression analysis reveals differences in the regulation of intestinal paraoxonase family members. Int J Biochem Cell Biol, 41:1628–1637. 2009.
269.
Primo-ParmoSL, SorensonRC, TeiberJ, La DuBN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 33:498–507. 1996.
270.
QinQ, LiYL, ZhaoFM, WangH, LiY, CuiRZ, ZhaoBR. [Association of paraoxonase polymorphisms and serum homocysteine thiolactone complex with coronary heart disease]Zhonghua Xin Xue Guan Bing Za Zhi, 34:803–807. 2006.
271.
RainwaterDL, RutherfordS, DyerTD, RainwaterED, ColeSA, VandebergJL, AlmasyL, BlangeroJ, MaccluerJW, MahaneyMC. Determinants of variation in human serum paraoxonase activity. Heredity, 102:147–154. 2009.
272.
RajavashisthTB, AndalibiA, TerritoMC, BerlinerJA, NavabM, FogelmanAM, LusisAJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature, 344:254–257. 1990.
273.
RamosP, GiesegSP, SchusterB, EsterbauerH. Effect of temperature and phase transition on oxidation resistance of low density lipoprotein. J Lipid Res, 36:2113–2128. 1995.
274.
RangaswamyS, PennMS, SaidelGM, ChisolmGM. Exogenous oxidized low-density lipoprotein injures and alters the barrier function of endothelium in rats in vivo. Circ Res, 80:37–44. 1997.
275.
RaoMN, MarmillotP, GongM, PalmerDA, SeeffLB, StraderDB, LakshmanMR. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism, 52:1287–1294. 2003.
276.
ReaIM, McKeownPP, McMasterD, YoungIS, PattersonC, SavageMJ, BeltonC, MarchegianiF, OlivieriF, BonafeM, FranceschiC. Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp Gerontol, 39:629–635. 2004.
277.
ReddyST, DevarajanA, BourquardN, ShihD, FogelmanAM. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?Curr Opin Lipidol, 19:405–408. 2008.
278.
ReddyST, WadleighDJ, GrijalvaV, NgC, HamaS, GangopadhyayA, ShihDM, LusisAJ, NavabM, FogelmanAM. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol, 21:542–547. 2001.
279.
RefsumH, SmithAD, UelandPM, NexoE, ClarkeR, McPartlinJ, JohnstonC, EngbaekF, SchneedeJ, McPartlinC, ScottJM. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem, 50:3–32. 2004.
280.
RensenSS, DoevendansPA, van EysGJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J, 15:100–108. 2007.
281.
RizosE, TambakiAP, GaziI, TselepisAD, ElisafM. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids, 72:203–209. 2005.
282.
RockW, RosenblatM, Miller-LotanR, LevyAP, EliasM, AviramM. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem, 56:8704–8713. 2008.
283.
RodrigoL, GilF, HernandezAF, LopezO, PlaA. Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties. Biochem J, 376:261–268. 2003.
284.
RodrigoL, HernandezAF, Lopez-CaballeroJJ, GilF, PlaA. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact, 137:123–137. 2001.
285.
RosenblatM, DraganovD, WatsonCE, BisgaierCL, La DuBN, AviramM. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol, 23:468–474. 2003.
286.
RosenblatM, HayekT, HusseinK, AviramM. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol, 24:175–180. 2004.
287.
RozenbergO, ShihDM, AviramM. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol, 23:461–467. 2003.
288.
RozenbergO, ShinerM, AviramM, HayekT. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic Biol Med, 44:1951–1959. 2008.
289.
SacksFM, TonkinAM, CravenT, PfefferMA, ShepherdJ, KeechA, FurbergCD, BraunwaldE. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation, 105:1424–1428. 2002.
290.
SakaiM, MiyazakiA, HakamataH, KodamaT, SuzukiH, KoboriS, ShichiriM, HoriuchiS. The scavenger receptor serves as a route for internalization of lysophosphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation. J Biol Chem, 271:27346–27352. 1996.
291.
SanderCS, ChangH, HammF, ElsnerP, ThieleJJ. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol, 43:326–335. 2004.
292.
SangvanichP, MacknessB, GaskellSJ, DurringtonP, MacknessM. The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. Biochem Biophys Res Commun, 300:501–506. 2003.
293.
SantanamN, ParthasarathyS. Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. Atherosclerosis, 191:272–275. 2007.
294.
SarandolE, SerdarZ, DiricanM, SafakO. Effects of red wine consumption on serum paraoxonase/arylesterase activities and on lipoprotein oxidizability in healthy-men. J Nutr Biochem, 14:507–512. 2003.
295.
SarandolE, TasS, DiricanM, SerdarZ. Oxidative stress and serum paraoxonase activity in experimental hypothyroidism: effect of vitamin E supplementation. Cell Biochem Funct, 23:1–8. 2005.
296.
SatohT, TaylorP, BosronWF, SanghaniSP, HosokawaM, La DuBN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos, 30:488–493. 2002.
297.
SchraderC, SchiborrC, FrankJ, RimbachG. Curcumin induces paraoxonase 1 in cultured hepatocytes in vitro but not in mouse liver in vivo. Br J Nutr, 105:167–170. 2011.
298.
SenokuchiT, MatsumuraT, SakaiM, MatsuoT, YanoM, KiritoshiS, SonodaK, KukidomeD, NishikawaT, ArakiE. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase mediate macrophage proliferation induced by oxidized low-density lipoprotein. Atherosclerosis, 176:233–245. 2004.
SeresI, ParaghG, DescheneE, FulopTJr., KhalilA. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol, 39:59–66. 2004.
301.
ShaposhnikZ, WangX, TriasJ, FraserH, LusisAJ. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002)J Lipid Res, 50:623–629. 2009.
ShihDM, GuL, HamaS, XiaYR, NavabM, FogelmanAM, LusisAJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest, 97:1630–1639. 1996.
304.
ShihDM, GuL, XiaYR, NavabM, LiWF, HamaS, CastellaniLW, FurlongCE, CostaLG, FogelmanAM, LusisAJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 394:284–287. 1998.
305.
ShihDM, Kast-WoelbernHR, WongJ, XiaYR, EdwardsPA, LusisAJ. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J Lipid Res, 47:384–392. 2006.
ShihDM, XiaYR, WangXP, WangSS, BourquardN, FogelmanAM, LusisAJ, ReddyST. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res, 100:1200–1207. 2007.
308.
ShinBS, OhSY, KimYS, KimKW. The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurol Scand, 117:237–243. 2008.
309.
ShinerM, FuhrmanB, AviramM. Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation into macrophages. Free Radic Biol Med, 37:2052–2063. 2004.
310.
ShinerM, FuhrmanB, AviramM. A biphasic U-shape effect of cellular oxidative stress on the macrophage anti-oxidant paraoxonase 2 (PON2) enzymatic activity. Biochem Biophys Res Commun, 349:1094–1099. 2006.
311.
ShinerM, FuhrmanB, AviramM. Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPAR gamma and AP-1 pathway activation. Atherosclerosis, 195:313–321. 2007.
312.
ShinerM, FuhrmanB, AviramM. Macrophage paraoxonase 2 (PON2) expression is upregulated by unesterified cholesterol through activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Biol Chem, 388:1353–1358. 2007.
313.
SierksmaA, van der GaagMS, van TolA, JamesRW, HendriksHF. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res, 26:1430–1435. 2002.
314.
SinanS, KockarF, ArslanO. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie, 88:565–574. 2006.
315.
SinanS, KockarF, GencerN, YildirimH, ArslanO. Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol Pharm Bull, 29:1559–1563. 2006.
316.
SinanS, KockarF, GencerN, YildirimH, ArslanO. Amphenicol and macrolide derived antibiotics inhibit paraoxonase enzyme activity in human serum and human hepatoma cells (HepG2) in vitro. Biochemistry (Mosc), 71:46–50. 2006.
317.
SorensonRC, AviramM, BisgaierCL, BilleckeS, HsuC, La DuBN. Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase. Chem Biol Interact, 119–120243–2491999.
318.
SorensonRC, BisgaierCL, AviramM, HsuC, BilleckeS, La DuBN. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol, 19:2214–2225. 1999.
319.
SorensonRC, Primo-ParmoSL, KuoCL, AdkinsS, LockridgeO, La DuBN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A, 92:7187–7191. 1995.
320.
SparrowCP, ParthasarathyS, SteinbergD. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem, 264:2599–2604. 1989.
321.
SteinbergD. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem, 272:20963–20966. 1997.
322.
StevensRC, SuzukiSM, ColeTB, ParkSS, RichterRJ, FurlongCE. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci U S A, 105:12780–12784. 2008.
323.
StubbsPJ, Al-ObaidiMK, ConroyRM, CollinsonPO, GrahamIM, NobleIM. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation, 102:605–610. 2000.
324.
SudaO, TsutsuiM, MorishitaT, TasakiH, UenoS, NakataS, TsujimotoT, ToyohiraY, HayashidaY, SasaguriY, UetaY, NakashimaY, YanagiharaN. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol, 24:1682–1688. 2004.
325.
SuehiroT, NakamuraT, InoueM, ShiinokiT, IkedaY, KumonY, ShindoM, TanakaH, HashimotoK. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis, 150:295–298. 2000.
TaburS, TorunAN, SabuncuT, TuranMN, CelikH, OcakAR, AksoyN. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol, 162:535–541. 2010.
329.
TeiberJF, DraganovDI, La DuBN. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol, 66:887–896. 2003.
330.
TeiberJF, DraganovDI, La DuBN. Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res, 45:2260–2268. 2004.
331.
TeiberJF, HorkeS, HainesDC, ChowdharyPK, XiaoJ, KramerGL, HaleyRW, DraganovDI. Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone. Infect Immun, 76:2512–2519. 2008.
332.
Thomas-MoyaE, Nadal-CasellasA, GianottiM, LladoI, ProenzaAM. Time-dependent modulation of rat serum paraoxonase 1 activity by fasting. Pflugers Arch, 453:831–837. 2007.
333.
TomasM, SentiM, ElosuaR, VilaJ, SalaJ, MasiaR, MarrugatJ. Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Eur J Pharmacol, 432:121–128. 2001.
334.
TougouK, NakamuraA, WatanabeS, OkuyamaY, MorinoA. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos, 26:355–359. 1998.
335.
TsaiJC, PerrellaMA, YoshizumiM, HsiehCM, HaberE, SchlegelR, LeeME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A, 91:6369–6373. 1994.
336.
TsakirisS, KarikasGA, ParthimosT, TsakirisT, BakogiannisC, SchulpisKH. Alpha-tocopherol supplementation prevents the exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthy individuals. Eur J Clin Nutr, 63:215–221. 2009.
337.
TsimihodimosV, KarabinaSA, TambakiAP, BairaktariE, GoudevenosJA, ChapmanMJ, ElisafM, TselepisAD. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol, 22:306–311. 2002.
338.
TurfanerN, UzunH, BalciH, ErcanMA, KarterYH, CanerM, SipahiogluF, GencH. Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South Med J, 103:428–433. 2010.
UndasA, BrozekJ, JankowskiM, SiudakZ, SzczeklikA, JakubowskiH. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol, 26:1397–1404. 2006.
341.
UngvariZ, CsiszarA, EdwardsJG, KaminskiPM, WolinMS, KaleyG, KollerA. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol, 23:418–424. 2003.
342.
van den BergSW, JansenEH, KruijshoopM, BeekhofPK, BlaakE, van der KallenCJ, van GreevenbroekMM, FeskensEJ. Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study)Diabet Med, 25:186–193. 2008.
343.
van der GaagMS, van TolA, ScheekLM, JamesRW, UrgertR, SchaafsmaG, HendriksHF. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis, 147:405–410. 1999.
344.
Van LentenBJ, NavabM, ShihD, FogelmanAM, LusisAJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med, 11:155–161. 2001.
345.
Van LentenBJ, WagnerAC, NavabM, FogelmanAM. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem, 276:1923–1929. 2001.
346.
van WijkJ, CollB, CabezasMC, KoningE, CampsJ, MacknessB, JovenJ. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol, 33:1134–1137. 2006.
347.
VaratharajaluR, GarigeM, LeckeyLC, GongM, LakshmanMR. Betaine protects chronic alcohol and omega-3 PUFA-mediated down-regulations of PON1 gene, serum PON1 and homocysteine thiolactonase activities with restoration of liver GSH. Alcohol Clin Exp Res, 34:424–431. 2010.
348.
VizzardiE, NodariS, FiorinaC, MetraM, Dei CasL. Plasma homocysteine levels and late outcome in patients with unstable angina. Cardiology, 107:354–359. 2007.
349.
VohlMC, NevilleTA, KumarathasanR, BraschiS, SparksDL. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry, 38:5976–5981. 1999.
WallaceAJ, SutherlandWH, MannJI, WilliamsSM. The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Eur J Clin Nutr, 55:951–958. 2001.
352.
WatsonAD, BerlinerJA, HamaSY, La DuBN, FaullKF, FogelmanAM, NavabM. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest, 96:2882–2891. 1995.
353.
WatsonCE, DraganovDI, BilleckeSS, BisgaierCL, La DuBN. Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogenetics, 11:123–134. 2001.
354.
WatzingerN, SchmidtH, SchumacherM, SchmidtR, EberB, FruhwaldFM, ZweikerR, KostnerGM, KleinW. Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community-based study. Cardiology, 98:116–122. 2002.
355.
WeissN, HeydrickSJ, PosteaO, KellerC, KeaneyJFJr., LoscalzoJ. Influence of hyperhomocysteinemia on the cellular redox state—impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med, 41:1455–1461. 2003.
356.
WillcoxMD, ZhuH, ConibearTC, HumeEB, GivskovM, KjellebergS, RiceSA. Role of quorum sensing by Pseudomonas aeruginosa in microbial keratitis and cystic fibrosis. Microbiology, 154:2184–2194. 2008.
357.
WojcickaG, Jamroz-WisniewskaA, MarciniakA, LowickaE, BeltowskiJ. The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity. Life Sci, 87:126–132. 2010.
358.
XiaY, GueguenR, Vincent-ViryM, SiestG, VisvikisS. Effect of six candidate genes on early aging in a French population. Aging Clin Exp Res, 15:111–116. 2003.
359.
YamadaM, SodeyamaN, ItohY, OtomoE, MatsushitaM, MizusawaH. No association of paraoxonase genotype or atherosclerosis with cerebral amyloid angiopathy. Stroke, 33:896–900. 2002.
YesilbursaD, SerdarA, SaltanY, SerdarZ, HeperY, GucluS, CordanJ. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol, 62:526–530. 2005.
362.
YoshidaH, QuehenbergerO, KondratenkoN, GreenS, SteinbergD. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol, 18:794–802. 1998.
363.
ZettlerME, ProciukMA, AustriaJA, ZhongG, PierceGN. Oxidized low-density lipoprotein retards the growth of proliferating cells by inhibiting nuclear translocation of cell cycle proteins. Arterioscler Thromb Vasc Biol, 24:727–732. 2004.
364.
ZhangJG, WangLZ, HanXQ, JiangYD, ZhangRM, WangSR. [The pathogenic mechanism of homocysteine -induced endothelial nitric oxide synthase dysfunction and the antagonistic effects by folic acid]Fen Zi Xi Bao Sheng Wu Xue Bao, 40:17–23. 2007.
ZhaoGF, SengJJ, ZhangH, SheMP. Effects of oxidized low density lipoprotein on the growth of human artery smooth muscle cells. Chin Med J (Engl), 118:1973–1978. 2005.
